A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MK-3475A in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Hyaluronidase/Pembrolizumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; MSD KK
Most Recent Events
- 04 Mar 2025 Planned End Date changed from 2 Mar 2027 to 31 Mar 2028.
- 04 Mar 2025 Planned primary completion date changed from 2 Mar 2027 to 31 Mar 2028.
- 25 Oct 2023 Status changed from not yet recruiting to recruiting.